Approval · Notice of Compliance 27455 · 2022
VEKLURY: Notice of Compliance 27455
Issued January 24, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27455
- Date
- January 24, 2022
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- To provide the Phase 3 clinical trial data in fulfillment of the conditions outlined in the Letter of Undertaking
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VEKLURY | Not yet assigned | — |
Medicinal ingredients
- REMDESIVIR 100 MG per VIAL